Donald Trump has escalated his trade war with a fresh blow to India’s pharma industry. In a new social media post, the U.S. President announced 100% tariffs on patented pharmaceutical exports starting October 1, exempting only firms that set up plants in America. This comes on top of the 50% tariffs already imposed on Indian goods. While the Indian pharma industry stresses that generics—90% of its U.S. exports—remain untouched, concerns are rising. Generics from India supply nearly half of all U.S. prescriptions, saving America $200 billion annually. Will Trump’s plan to raise tariffs further to 150% or even 250% derail India’s multi-billion-dollar pharma exports? Watch the full analysis.

See Full Page